SVCM
CBAY

Saturn V Capital Management’s Cymabay Therapeutics CBAY Stock Holding History

Saturn V Capital Management’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-750,250
Closed -$17.7M – 27
2023
Q4 		$17.7M Sell
750,250
-374,209
-33% -$6.66M 6.78% 5
2023
Q3 		$16.8M Sell
1,124,459
-63,342
-5% -$840K 7.02% 4
2023
Q2 		$13M Sell
1,187,801
-441,663
-27% -$4.11M 7.21% 5
2023
Q1 		$14.2M Buy
1,629,464
+17,686
+1% +$142K 10.61% 1
2022
Q4 		$5.72M Buy
+1,611,778
New +$6.13M 4.75% 12

Other funds holding CBAY

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Saturn V Capital Management's CBAY Position: Q1 2024 in Review

Saturn V Capital Management sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 750,250 shares — an estimated $17.7M sold.

Saturn V Capital Management first reported a position in CBAY in Q4 2022 and held it in 5 quarters. The position peaked at $17.7M in Q4 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.

  • Saturn V Capital Management reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Saturn V Capital Management sold 750,250 Cymabay Therapeutics shares in Q1 2024, an estimated $17.7M.
  • Saturn V Capital Management first reported a position in Cymabay Therapeutics in Q4 2022 and held it in 5 quarters.
  • Saturn V Capital Management's Cymabay Therapeutics position peaked at $17.7M in Q4 2023.
  • 1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.

Based on Saturn V Capital Management's 13F filing for Q1 2024, filed 15 May 2024.